# A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

> **NCT02033551** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 47 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Colon Cancer
- Lung Cancer
- Gastric Cancer
- Solid Tumors

## Interventions

- **DRUG:** Veliparib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT02033551
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033551, "A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02033551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*